Lupin Expands Global Diabetes Footprint with Semaglutide Deal

💊

has entered into a licensing and supply agreement with Galenicum Health for injectable Semaglutide across 23 international markets, including Canada, Europe, Southeast Asia, and Latin America. The partnership strengthens Lupin’s global presence in diabetes care and aligns with its strategy to scale complex generics and specialty offerings.